This week’s Nature had an article critical of the
new $1 billion cancer cure project from the Obama administration. I agree with
the journal. While one sympathizes completely with VP Biden’s recent tragic
loss of his son to cancer, this is not the way to move forward. As in the past,
throwing big bucks at cancer will probably involve large scale, multi-investigator
‘translational’ research projects that are often inefficient and unproductive. What will ultimately benefit cancer patients
is continuing research on basic molecular mechanisms of cancer and how to alter
those mechanisms. For example, the recent evolution of the CRISPR gene editing
technology, a basic research discovery, is likely to have a greater positive
impact on cancer therapy than many of the more applied projects sponsored by
the NCI.
Science For The Future: A Science Policy Blog
This blog will deal with the social, economic and public policy implications of contemporary science and technology with an emphasis on biomedical aspects.
Friday, February 19, 2016
Friday, January 29, 2016
More Bad News for Biomedical PhDs
A recent article in SCIENCE provided a thorough study
of several thousand early career PhD graduates from several large public
universities. I guess the good news is that most of them were not employed at
McDonalds or Walmart. However, the bad news is the paltry salaries that many
young PhDs are receiving, particularly those in the biomedical sciences.
Most newly minted biomedical PhDs go on to do
academic postdoctoral stints, so it is not surprising that this group has low
wages. However, according to the study about 25% of graduates go into industry
where one would expect higher wages. To be sure industrial salaries are higher
than academic postdocs, but they still run in the $50-75,000 range. Considering
that a PhD is a 4-7 year investment, it is interesting to compare industry
salaries for early stage PhDs with those of a postman ($51,790).
The low salaries no doubt reflect the laws of supply
and demand. With universities continuing to churn out PhDs the value of the
degree is diluted. Overproduction of PhDs in the biomedical sciences, as well
as industry driven importation of low wage foreign workers especially in
computer science, both drive down salaries.
This is an old story that has been commented on
several times in this blog—but nothing seems to change.
Monday, June 8, 2015
Yes Paul Ehrlich Was Right! Its Just a Matter of Timing.
The NY Times had an Opinion
Page today on whether overpopulation is a threat, with mixed opinions being expressed
I don’t understand how there
can even be a debate on this?
Population growth is not
slowing as rapidly as the experts expected. The UN keeps revising its
population projections upward.
The billions in Asia, Latin
America and Africa will not be denied their chance to experience the
consumerist life style long enjoyed by developed countries.
The net result will be the
complete destruction of the natural world. Will humans survive? Probably- but
living on yeast protein and cowering from the mega-storms unleashed by global
warming.
Friday, June 5, 2015
CRISPR–Mania
As described in a recent
article in Nature, the advent of a
powerful gene editing technique based on the CRISPR-Cas9 system is leading to a
revolution in molecular biology and possibly in medicine. For a couple of
decades scientists have known how to introduce or modify genes in cells by a
process called homologous recombination.
When done in stem cells, the gene modified cells can be re-implanted and
can give rise to tissues, including reproductive tissues, and thus eventually
to genetically modified organisms. A major problem is that the entire process
is very inefficient. Several previous attempts to increase the efficiency of
gene editing have involved ‘designed’ proteins such as the Talens nucleases or
zinc finger nucleases that can cut DNA at specific sites thus creating
opportunities for recombination. However, preparing these designed proteins is
difficult and time consuming.
The great advantage of the
CRISPR-Cas system is that it uses a short RNA molecule to target the site in
DNA that needs to be cut, with the cutting provided by the Cas enzyme. It’s easy to design RNAs that can hybridize
with specific DNA sites, and the entire CRISPR-Cas system can be engineered
into a viral vector that is also quite easy to use. Thus this approach has revolutionized
laboratory practices for gene modification in cells for basic research
purposes.
CRISPR can also impact in
vivo studies. For example, an animal with a gene defect can provide stem cells.
The stem cell gene can be ‘corrected’ in the lab using CRISPR and the corrected
stem cells re-infused into animals. Potentially the stem cells can then engraft
in tissues and thus fully or partially correct the defect in the animal. This
has already been done in a number of studies in mice. Obviously the same is potentially possible in
humans but has not yet been done. Some
investigators have tried to correct genetic defects in mice by directly
injecting the entire CRISPR-Cas9 system, but this is very inefficient in its
current state of development.
The very power of this
technique is beginning to cause ethical concerns. For example a group in China reported
editing the genes of human embryos. The potential for this type of activity has
caused leading scientists in CRISPR research to advocate restraint and careful
design of projects to avoid risks to humans.
The CRISPR-Cas technology
clearly has enormous potential. However, it needs to be viewed in the same
perspective as all new biomedical technologies. Monoclonal antibodies, siRNA,
nanomedicine- each of these potentially transformative technologies has followed
the same path, with an initial period of almost irrational exuberance, followed
by disillusionment as problems inevitably emerged, followed by a more
considered assessment of ultimate therapeutic potential. So will it be with CRISPR.
Friday, May 29, 2015
Smart Machines Getting Too Smart For Humans?
This
week’s Nature has a section on ethical
aspects of robotics and artificial intelligence. Reading this article, the
associated comments, and the accompanying special section on Machine
Intelligence in this week’s issue, has left me deeply concerned. The
accelerating capabilities of both individual intelligent machines and the
Internet itself raise all sorts of questions about whether human beings will be
better off or not if artificial intelligence continues to evolve in its current
uncontrolled fashion. It seems we need a
measured assessment of both the potentials and hazards of this thrust before we
proceed much further. Clearly it is always difficult to accurately anticipate
the path of an emerging technology and to create guidelines concerning its
development and implementation. Nonetheless society has done this previously in
the context of other transformative technologies such as nuclear weapons and
genetic engineering. Although there is plenty of hype in the media, it surprises
me how little the issue of Artificial Intelligence has been addressed by
ethicists or by governmental bodies.
Friday, May 22, 2015
Antibiotic Resistance: Big Pharma Fails to Address the Challenge
A recent report in SCIENCE
is another example of ‘Big Pharma’ failing to address important public health
issues. The problem of resistance to
conventional antibiotics is reaching crisis proportions, accelerated by the
widespread use of antibiotics in mass agriculture. The technology to develop
powerful new drugs is there, but the profit motivation is not. In many respects this situation is similar to
the problem of developing medications for diseases such as malaria that
primarily affect poorer countries and thus provide little opportunity for large
profits. It is encouraging to learn that some governments are seeking ways to
break the roadblock on antibiotic development. However, is this enough? One might argue that this key area of drug
research be pursued through innovative public funding rather than be left to
the dictates of Wall Street.
http://www.sciencemag.org/content/348/6237/850.full
http://www.sciencemag.org/content/348/6237/850.full
Thursday, March 5, 2015
Global Warming? Capitalism to the Rescue!
In a very interesting article
in Nature (1) Nathan Fabian discusses
the role of global investors in the transition from a high carbon to a low
carbon economy. He points out that
capital investments are trending toward lower emission energy sources such as
solar and away from high emission sources such as coal. This is happening not
because of the investor’s altruism but because of cold calculation about
risk/reward ratios. Basically green energy may be a safer bet than coal for the
long run.
However, the capitalist
calculations are inevitably based on government policies. As the article admits,
the expectation of political actions such as instituting carbon taxes, removing
subsidies to oil and coal industries, and providing subsidies to green energy
development are part of the investor’s calculus. Thus, as usual, it is up to
governments to channel the behavior of capitalists into socially productive
pathways.
(1)
http://www.nature.com/news/economics-support-low-carbon-investment-1.17015
Subscribe to:
Posts (Atom)